Track market-moving stories before they get noisy

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today reported positive initial Phase 1b clinical trial results for ALN-HTT02, an investigational RNAi therapeutic in development for the treatment of Huntington's disease, which will be developed under the International Nonproprietary Name (INN) brezosiran (bre-ZOH-sir-an). The data were presented in oral and poster presentations at the European Huntington's Disease Network (.

It's been a horrible, lousy, rotten year so far for Alnylam Pharmaceuticals (ALNY -1.11%) investors. Feel free to add any other similar adjectives you'd like.

Alnylam's share price has plunged more than 40% year to date. Only one other large-cap stock in the entire healthcare sector has performed worse. Alnylam's impressive 69% gain in 2025 has been almost completely erased.

The drugmaker's financials look great. It's now solidly profitable. But investors are clearly treating Alnylam like it's a broken biotech stock.

Image source: Getty Images.

Just how profitable is Alnylam? Not long ago, Alnylam was hemorrhaging cash. The company posted net losses throughout 2024. As recently as the second quarter of last year, Alnylam's bottom line reflected a net loss of $16.2 million based on generally accepted accounting principles (GAAP).

However, Alnylam has experienced a dramatic transformation in profitability since then. It recorded impressive earnings of $251 million in the third quarter of 2025. This total was significantly boosted by funds received from its collaboration with Roche (RHHBY +3.45%).

But Alnylam remained profitable going forward, relying less on collaboration revenue. Sales skyrocketed for Amvuttra as it gained momentum in the transthyretin amyloid cardiomyopathy (ATTR-CM) market.

In the second quarter of 2026, Alnylam's GAAP net income totaled $164.5 million. Its adjusted earnings were much higher at $251.8 million. Meanwhile, the company's revenue soared 67% year over year to $1.29 billion. As icing on the cake, Alnylam's cash position (including cash, cash equivalents, and marketable securities) stood at $3.3 billion at the end of the quarter.

ALNY Alnylam Pharmaceuticals$230.71-$2.58 (-1.11%)

NASDAQ · As of 4:00 PM ET 10/20/26

Why Alnylam is being treated like a broken biotech If you only looked at Alnylam's financial statements, you'd probably conclude that everything is sunshine and roses for the drugmaker. So why is Alnylam being treated like a broken biotech? There are two main reasons -- and I think each of them is overstated.

First, in Q2, Alnylam cut its 2026 full-year revenue guidance for Amvuttra and Onpattra. Management had projected sales of $4.4 billion to $4.7 billion but lowered the outlook to $4.2 billion to $4.5 billion. CEO Yvonne Greenstreet said that the change was due to demand normalization after an initial spike of previously untreated ATTR-CM patients switching to Amvuttra.

Importantly, Amvuttra's sales continue to grow robustly. However, Alnylam's management team simply underestimated how the initial pent-up demand would turbocharge sales before stabilizing.

The second reason behind Alnylam's sinking share price this year is concern about disappointing Phase 3 results for Wainua (eplontersen) in treating ATTR-CM. Wainua isn't Alnylam's drug, by the way: It's marketed by AstraZeneca (AZN +2.97%) and Ionis Pharmaceuticals (IONS +2.30%). However, some investors worried that Wainua's setback in ATTR-CM could lower the chances of success for Alnylam's nucresiran, which is currently in late-stage testing as a treatment for ATTR-CM and hereditary ATTR amyloidosis with polyneuropathy (ATTR-PN).

To be sure, nucresiran might run into similar problems as Wainua. However, the two drugs use different mechanisms. Their clinical trials were designed differently. If Alnylam sees something in the details of the Wainua ATTR-CM study, it could adjust its nucresiran study, if appropriate.

A better story than the stock chart suggests While many investors view Alnylam as broken, Wall Street doesn't. Of the 23 analysts who have rated the stock over the past three months, 19 recommended buying it. The average 12-month price target for Alnylam reflects a potential upside of 54%. Piper Sandler's (PIPR +1.10%) Edward Tenthodd even thinks the stock could more than double over the next 12 months.

Alnylam remains strong financially. Its products, particularly Amvuttra, continue to generate robust growth. The company's pipeline is promising. All things considered, I think Alnylam has a much better story than its stock chart suggests.

First Citizens Bank & Trust Co. bought a new position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Free Report) during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm bought 2,874 shares of the biopharmaceutical company’s stock, valued at approximately $709,000.

Several other hedge funds have also recently bought and sold shares of ALNY. SCS Capital Management LLC acquired a new stake in shares of Alnylam Pharmaceuticals during the second quarter valued at about $34,784,000. Mitsubishi UFJ Asset Management Co. Ltd. bought a new stake in shares of Alnylam Pharmaceuticals in the 2nd quarter valued at approximately $50,773,000. Silvant Capital Management LLC acquired a new stake in shares of Alnylam Pharmaceuticals during the second quarter worth $5,456,000. Hsbc Holdings PLC raised its stake in Alnylam Pharmaceuticals by 22.6% during the fourth quarter. Hsbc Holdings PLC now owns 89,517 shares of the biopharmaceutical company’s stock worth $35,675,000 after acquiring an additional 16,503 shares during the period. Finally, Wealthfront Advisers LLC acquired a new stake in shares of Alnylam Pharmaceuticals during the 2nd quarter worth approximately $2,876,000. Hedge funds and other institutional investors own 92.97% of the company’s stock.

Wall Street Analyst Weigh In ALNY has been the topic of a number of recent analyst reports. Barclays dropped their price target on shares of Alnylam Pharmaceuticals from $527.00 to $450.00 and set an “overweight” rating on the stock in a research report on Monday, August 3rd. Stifel Nicolaus dropped their price target on Alnylam Pharmaceuticals from $444.00 to $318.00 and set a “buy” rating on the stock in a research note on Friday, July 31st. Chardan Capital restated a “buy” rating and issued a $425.00 target price on shares of Alnylam Pharmaceuticals in a report on Friday, July 31st. BMO Capital Markets reiterated an “outperform” rating on shares of Alnylam Pharmaceuticals in a research report on Monday, August 31st. Finally, JPMorgan Chase & Co. dropped their price objective on Alnylam Pharmaceuticals from $375.00 to $369.00 and set an “overweight” rating on the stock in a report on Wednesday, September 30th. Three research analysts have rated the stock with a Strong Buy rating, seventeen have given a Buy rating and six have given a Hold rating to the company. According to MarketBeat.com, Alnylam Pharmaceuticals has a consensus rating of “Moderate Buy” and an average price target of $364.95.

View Our Latest Analysis on ALNY Insider Transactions at Alnylam Pharmaceuticals In other news, EVP Bryan Supran sold 1,758 shares of the company’s stock in a transaction that occurred on Friday, October 2nd. The stock was sold at an average price of $226.88, for a total transaction of $398,855.04. Following the sale, the executive vice president owned 12,807 shares in the company, valued at $2,905,652.16. This represents a 12.07% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders own 0.86% of the company’s stock.

Alnylam Pharmaceuticals Stock Down 0.9% ALNY opened at $231.83 on Friday. The company has a debt-to-equity ratio of 0.75, a quick ratio of 2.99 and a current ratio of 3.05. The firm has a market cap of $31.02 billion, a price-to-earnings ratio of 43.09 and a beta of 0.28. Alnylam Pharmaceuticals, Inc. has a twelve month low of $197.81 and a twelve month high of $495.55. The firm’s 50-day simple moving average is $239.35 and its 200-day simple moving average is $274.34.

Alnylam Pharmaceuticals (NASDAQ:ALNY – Get Free Report) last announced its earnings results on Thursday, July 30th. The biopharmaceutical company reported $1.84 earnings per share for the quarter, topping analysts’ consensus estimates of $1.63 by $0.21. Alnylam Pharmaceuticals had a net margin of 15.26% and a return on equity of 84.93%. The company had revenue of $1.29 billion during the quarter, compared to the consensus estimate of $1.32 billion. During the same period in the previous year, the firm posted ($0.51) earnings per share. The company’s revenue was up 66.9% on a year-over-year basis. Equities research analysts anticipate that Alnylam Pharmaceuticals, Inc. will post 6.68 EPS for the current fiscal year.

(Free Report)

Alnylam Pharmaceuticals, Inc is a biopharmaceutical company focused on developing and commercializing medicines based on RNA interference (RNAi), a biological process that can selectively reduce the production of disease-causing proteins. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.

Alnylam’s commercial products include ONPATTRO (patisiran), an RNAi therapy for hereditary transthyretin-mediated amyloidosis with polyneuropathy; GIVLAARI (givosiran), for acute hepatic porphyria; OXLUMO (lumasiran), for primary hyperoxaluria type 1; and AMVUTTRA (vutrisiran), for transthyretin-mediated amyloidosis.

Featured Articles Five stocks we like better than Alnylam Pharmaceuticals Bank of America Stock Sell-Off Looks Like a Buying Opportunity AST SpaceMobile Is Down 67%—Could SpaceX’s Mobile Push Deepen the Selloff? GlobalFoundries’ $21 Billion Deal Could Change the Economics of Chipmaking Fundamental and Technicals Signals Align for Costco: Is the Stock Finally Breaking Out?

Receive News & Ratings for Alnylam Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Perhaps the best word to describe the performances of Alnylam Pharmaceuticals (ALNY +3.63%) and Ionis Pharmaceuticals (IONS +4.57%) in 2026 is "ouch." Both stocks have sunk like a brick year to date. The common denominator behind Alnylam's and Ionis' dismal returns is that each company has experienced its fair share of bad news.

In July, Alnylam cut its revenue guidance due to lower-than-expected sales of its flagship drug, Amvuttra. Ionis experienced two clinical setbacks on the same day, July 9, 2026: Eplontersen failed to meet its primary endpoint in a Phase 3 study for treating transthyretin amyloid cardiomyopathy (ATTR-CM), while Roche (RHHBY +1.35%) threw in the towel on a Huntington's disease drug developed by Ionis.

Which of these two beaten-down biotech stocks is the better bad-news buy? Here's how Alnylam and Ionis stack up against each other.

Image source: Getty Images.

There's a clear winner between these two stocks on the financial front. Alnylam's revenue soared 74% year over year in its latest quarter to $1.17 billion. The company posted adjusted earnings of $251.8 million. Meanwhile, Ionis' revenue declined by roughly 41% year over year in the second quarter of 2026 to $268 million, with an adjusted quarterly loss of $57 million.

Premium Feature

Moneyball Superscore

81/100

Today's Change

(

3.63

%) $

8.15

Current Price

$

232.68

Granted, Ionis' year-over-year comparison was hurt by a one-time upfront payment for its experimental therapy sapablursen recognized in 2025 Q2. Still, though, Alnylam has the undisputed financial edge.

Which company's news was worse? You could argue that Alnylam's slower-than-anticipated revenue for its top product, Amvuttra, was a bigger blow than Ionis' setbacks for its two partnered programs. However, Amvuttra's sales continue to skyrocket.

Also, Alnylam's competitive dynamics have improved thanks to two developments. Pfizer (PFE +1.65%) won't have generic competition for tafamidis until mid-2031, which helps Alnylam. Importantly, the disappointing late-stage results announced by AstraZeneca (AZN +0.27%) and Ionis for eplontersen could work to the benefit of Alnylam's late-stage candidate, nucresiran.

Wall Street favors Ionis, though. Of the 21 analysts who have given ratings over the past three months, 17 recommended Ionis as a "buy" or better. Their average 12-month price target reflected a potential upside of roughly 88%. Analysts were also bullish about Alnylam, with 18 of 22 analysts rating the stock as a "buy" or better. However, the consensus price target was around 61% above the share price as of Tuesday, Oct. 6, 2026.

Premium Feature

Moneyball Superscore

72/100

Today's Change

(

4.57

%) $

1.98

Current Price

$

45.28

Better bad-news buy The sell-offs for both of these growth stocks are overdone, in my view. I predict that both stocks will be market-beating winners over the next few years.

If I could only pick one of them, though, I'd go with Alnylam. Wall Street may be right that Ionis has more near-term upside potential, but I think Alnylam offers the more attractive risk-reward proposition.

Keith Speights has positions in Pfizer. The Motley Fool has positions in and recommends Alnylam Pharmaceuticals, AstraZeneca Plc, Ionis Pharmaceuticals, and Pfizer. The Motley Fool recommends Roche Holding AG. The Motley Fool has a disclosure policy.

LOS ANGELES, Oct. 05, 2026 (GLOBE NEWSWIRE) -- Glancy Prongay Wolke & Rotter LLP, a leading national shareholder rights law firm, continues its investigation on behalf of Alnylam Pharmaceuticals, Inc. (“Alnylam” or the “Company”) (NASDAQ: ALNY) investors concerning the Company’s possible violations of the federal securities laws.

IF YOU ARE AN INVESTOR WHO LOST MONEY ON ALNYLAM PHARMACEUTICALS, INC. (ALNY), CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING CLAIMS TO RECOVER YOUR LOSS.

What Happened?
On July 30, 2026, Alnylam announced second quarter 2026 financial results. Among other things, the Company reported it has “lowered our TTR product sales guidance for full-year 2026 to reflect learnings from the initial phase of our launch in the evolving ATTR-CM market, in particular the normalization of growth in second line volume after satisfying pent-up demand from patients waiting for a new therapy.” As a result, the Company lowered its total projected TTR net product revenues by approximately $200 million.

On this news, shares of Alnylam fell $81.14 or 28.31%, to close at $205.48 on July 30, 2026, thereby injuring investors.

Contact Us To Participate or Learn More:
If you wish to learn more about this action, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact us.
Charles Linehan, Esq.,
Glancy Prongay Wolke & Rotter LLP,
1925 Century Park East, Suite 2100,
Los Angeles California 90067
Email:  [email protected]
Telephone: 310-201-9150 (Toll-Free: 888-773-9224)
Visit our website at www.glancylaw.com.
Follow us for updates on LinkedIn, Twitter, or Facebook.

Whistleblower Notice
Persons with non-public information regarding Alnylam Pharmaceuticals, Inc. should consider their options to aid the investigation or take advantage of the SEC Whistleblower Program. Under the program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Charles H. Linehan at 310-201-9150 or 888-773-9224 or email [email protected].

About Glancy Prongay Wolke & Rotter LLP
Glancy Prongay Wolke & Rotter LLP (“GPWR”) is a premier law firm representing investors and consumers in securities litigation and other complex class action litigation. GPWR has been consistently ranked in the Top 50 Securities Class Action Settlements by ISS Securities Class Action Services. In 2018, GPWR was ranked a top five law firm in number of securities class action settlements, and a top six law firm for total dollar size of settlements.

With four offices across the country, GPWR’s nearly 40 attorneys have won groundbreaking rulings and recovered billions of dollars for investors and consumers in securities, antitrust, consumer, and employment class actions. GPWR’s lawyers have handled cases covering a wide spectrum of corporate misconduct and relating to nearly all industries and sectors. GPWR’s past successes have been widely covered by leading news and industry publications such as The Wall Street Journal, The Financial Times, Bloomberg Businessweek, Reuters, the Associated Press, Barron’s, Investor’s Business Daily, Forbes, and Money.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contact Us:
Glancy Prongay Wolke & Rotter LLP,
1925 Century Park East, Suite 2100,
Los Angeles, CA 90067
Charles Linehan
Email:  [email protected]
Telephone: 310-201-9150
Toll-Free: 888-773-9224
Visit our website at: www.glancylaw.com.

LOS ANGELES, Oct. 02, 2026 (GLOBE NEWSWIRE) -- The Law Offices of Frank R. Cruz continues its investigation of Alnylam Pharmaceuticals, Inc. (“Alnylam” or the “Company”) (NASDAQ: ALNY) on behalf of investors concerning the Company’s possible violations of federal securities laws.

IF YOU ARE AN INVESTOR WHO LOST MONEY ON ALNYLAM PHARMACEUTICALS, INC. (ALNY), CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING A CLAIM TO RECOVER YOUR LOSS.

What Is The Investigation About?
On July 30, 2026, Alnylam announced second quarter 2026 financial results. Among other things, the Company reported it has “lowered our TTR product sales guidance for full-year 2026 to reflect learnings from the initial phase of our launch in the evolving ATTR-CM market, in particular the normalization of growth in second line volume after satisfying pent-up demand from patients waiting for a new therapy.” As a result, the Company lowered its total projected TTR net product revenues by approximately $200 million.

On this news, shares of Alnylam fell $81.14 or 28.31%, to close at $205.48 on July 30, 2026, thereby injuring investors.

Contact Us To Participate or Learn More:
If you purchased Alnylam Pharmaceuticals, Inc. securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact us:
The Law Offices of Frank R. Cruz,
2121 Avenue of the Stars, Suite 800,
Century City, California 90067
Call us at: 310-914-5007
Email us at: [email protected]
Visit our website at: www.frankcruzlaw.com.
Follow us for updates on Twitter at twitter.com/FRC_LAW.

If you inquire by email, please include your mailing address, telephone number, and number of shares purchased.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contact Us:
The Law Offices of Frank R. Cruz, Los Angeles
Frank R. Cruz
310-914-5007
[email protected]
www.frankcruzlaw.com

Key Takeaways Alnylam's RNAi portfolio generated $2.21 billion in first-half 2026 product revenues, up 94%.Ionis reported 185% growth in first-half product sales as Tryngolza and Dawnzera gained traction.Wave and Arcturus advance clinical RNA programs in obesity, OTC deficiency and other diseases. RNA therapeutics are medicines that use RNA molecules to influence gene expression or protein production. Unlike many conventional drugs that act directly on proteins, RNA medicines can intervene earlier in the process by reducing disease-causing proteins, modifying RNA or providing instructions to produce therapeutic proteins. This programmable approach can expand the range of disease targets available to drug developers.

Advances in RNA design and delivery have improved the stability, specificity and durability of these medicines. Key approaches include antisense oligonucleotides (ASOs) and RNA interference (RNAi), which regulate protein production. mRNA provides instructions to produce therapeutic proteins. RNA editing makes targeted changes to RNA without permanently altering DNA. These technologies are expanding into cardiovascular, metabolic, neurological and infectious diseases.

Against this backdrop, Alnylam Pharmaceuticals (ALNY - Free Report) , Ionis Pharmaceuticals (IONS - Free Report) , Wave Life Sciences (WVE - Free Report) and Arcturus Therapeutics (ARCT - Free Report) offer exposure to several of the most important branches of RNA medicine. Their platforms span RNAi, antisense technology, RNA editing and mRNA, while their pipelines extend RNA-based treatment into cardiometabolic, neurological, rare and respiratory diseases. The mix of commercial validation and advancing clinical programs gives these companies multiple avenues to participate in the continued expansion of RNA therapeutics. All four companies currently carry a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Alnylam PharmaceuticalsAlnylam is a pioneer in RNAi therapeutics, using small interfering RNA molecules to silence specific genes involved in disease. The company has already demonstrated the technology’s commercial potential through its RNAi products portfolio. Its commercial RNA franchise includes Amvuttra (vutrisiran) for hereditary transthyretin-mediated amyloidosis with polyneuropathy (hATTR-PN) and transthyretin amyloidosis with cardiomyopathy (ATTR-CM), Onpattro (patisiran) for hATTR-PN, Givlaari (givosiran) for acute hepatic porphyria and Oxlumo (lumasiran) for primary hyperoxaluria type 1. Alnylam generated $2.21 billion in global net product revenues in the first half of 2026, up 94% year over year, driven primarily by Amvuttra sales with increased patient demand mainly among ATTR-CM patients in the United States.

Alnylam also has a broad RNAi pipeline spanning cardiometabolic, neurological and bleeding disorders. Nucresiran is currently being evaluated in two phase III studies for hATTR-PN and ATTR-CM, while zilebesiran is being evaluated in a phase III study to reduce cardiovascular risk in patients with uncontrolled hypertension on two or more antihypertensives, one being a diuretic. In earlier-stage development, mivelsiran is being evaluated in separate phase II studies for cerebral amyloid angiopathy and Down syndrome-associated Alzheimer’s disease. At the same time, ALN-6400 is being evaluated in two separate mid-stage studies for hereditary hemorrhagic telangiectasia (HHT) and von Willebrand disease with heavy menstrual bleeding. Alnylam plans to report initial phase I data for ALN-HTT02 in Huntington’s disease in October 2026. Initial results from the phase II HHT study of ALN-6400 are also anticipated in the second half of 2026, providing another near-term pipeline catalyst.

Ionis PharmaceuticalsIonis is a pioneer in ASOtechnology, developing RNA-targeted medicines designed to bind specific RNA sequences and regulate the production of disease-associated proteins. Its RNA commercial portfolio includes Tryngolza (olezarsen) for adults with severe hypertriglyceridemia and familial chylomicronemia syndrome and Dawnzera (donidalorsen) for prevention of hereditary angioedema attacks in patients aged 12 years and older. Earlier this month, the FDA approved Zanvastro (zilganersen) as the first and only disease-modifying treatment for Alexander disease in pediatric and adult patients. Ionis also receives royalties from Wainua (eplontersen), marketed with AstraZeneca for hereditary transthyretin amyloidosis with polyneuropathy and Spinraza (nusinersen), marketed by Biogen for spinal muscular atrophy. Ionis reported $74 million in first-half 2026 total product sales, up 185% year over year, driven by strong Tryngolza and Dawnzera sales.

Ionis has several additional RNA-targeted medicines in development. Last week, the company reported positive top-line results from the phase III FUSION study of ulefnersen for people living with FUS-associated amyotrophic lateral sclerosis, demonstrating a statistically significant improvement on the primary endpoint assessing functional impairment and survival versus placebo, supporting the potential to modify disease progression. Ionis and partner Otsuka plan to discuss the results with the FDA and other health authorities to pursue potential expedited regulatory submission pathways for approval. Another late-stage candidate, obudanersen, is being evaluated in phase III for Angelman syndrome, with top-line data expected in the second half of 2027. Earlier-stage pipeline candidates include ION775, a next-generation siRNA targeting apoC-III, which is undergoing phase II development for severe hypertriglyceridemia. Meanwhile, GSK’s bepirovirsen, an antisense medicine for chronic hepatitis B developed in collaboration with Ionis, is currently under FDA Priority Review, with a decision expected on Oct. 26, 2026.

Wave Life SciencesWave Life Sciences is advancing next-generation RNA medicines through its PRISM platform, which combines multiple RNA-targeting modalities with proprietary chemistry and insights from human genetics. The platform includes RNA editing, RNAi, antisense and splicing technologies, enabling the company to pursue a range of therapeutic approaches across rare and common diseases.

Wave Life Sciences has no marketed RNA product, so its investment case is heavily dependent on clinical execution. WVE-006, a GalNAc-conjugated RNA-editing oligonucleotide, is being evaluated in the phase Ib/IIa RestorAATion-2 study in alpha-1 antitrypsin deficiency patients with the Pi*ZZ mutation. In May 2026, Wave Life Sciences reported encouraging clinical data demonstrating dose-dependent efficacy. Data from the 600-mg monthly multidose cohort are expected in the second half of 2026, while the company is also advancing regulatory discussions with the FDA on a potential accelerated-approval pathway. WVE-007, a GalNAc-siRNA targeting INHBE, is being evaluated in a phase IIa study as a monotherapy for obesity. Wave Life Sciences has also initiated a separate phase IIa study combining WVE-007 with Eli Lilly’s tirzepatide for obesity and plans to initiate a phase II study evaluating WVE-007 as a post-incretin maintenance therapy in the second half of 2026.

Arcturus TherapeuticsArcturus focuses on mRNA medicines, supported by its LUNAR lipid-mediated delivery system and STARR self-amplifying mRNA technology. The company developed Kostaive (zapomeran/ARCT-154), a self-amplifying mRNA vaccine for the prevention of COVID-19. Arcturus regained global rights to Kostaive from CSL Seqirus in 2026 following the termination of their collaboration. However, its first-half financials primarily reflected collaboration and grant revenues rather than direct Kostaive product sales. Arcturus reported $5 million of total revenues in the first half of 2026, down sharply from $57.7 million a year earlier, largely because of lower collaboration revenues following the wind-down of its CSL Seqirus arrangement.

Arcturus’ current therapeutics pipeline is entirely focused on RNA-based candidates. ARCT-810 is an intravenously administered mRNA therapeutic in phase II development for ornithine transcarbamylase (OTC) deficiency. Last week, the company reported interim data showing that ARCT-810 reduced and/or maintained first-morning fasting ammonia within the normal range. Arcturus plans to add ARCT-2601, a next-generation mRNA therapeutic for OTC deficiency, to the ongoing phase II study of ARCT-810 in OTC deficiency near year-end 2026, under an amended study protocol. ARCT-032, an inhaled mRNA therapeutic for cystic fibrosis in patients with Class I mutations, remains in phase II, with a decision on advancing the candidate to phase III expected in fourth-quarter 2026.

There's good news and bad news if you own shares of Alnylam Pharmaceuticals (ALNY +2.55%). The good news is that the biotech stock is up around 25% since the end of July. The bad news is that Alnylam is still down 35% year-to-date, even with that rebound. Ouch.

Has Wall Street soured on Alnylam? Not at all. Of the 21 analysts who have rated the stock over the last three months, 18 recommended it as a "buy" or "strong buy." Here's why I think these analysts are right to be bullish about Alnylam.

Image source: Getty Images.

Bully for the Alnylam bulls One reason why I'm on the same page as most analysts when it comes to Alnylam is the stock's valuation. Alnylam's shares trade at only 19.7 times forward earnings, which is cheap for a growth stock. Speaking of growth, its price-to-earnings-to-growth (PEG) ratio, which is based on analysts' five-year earnings growth projections, is a super-low 0.32.

The market dynamics have also shifted in Alnylam's favor this year. For example, Pfizer (PFE +0.92%) won't have generic competition for its Vyndamax franchise until mid-2031. That means Alnylam's Amvuttro won't potentially face disruption to its growth trajectory, either.

Another positive on this front is that a potential future rival now seems to be out of the picture. AstraZeneca (AZN +1.23%) and Ionis Pharmaceuticals (IONS +1.57%) reported in July 2026 that Wainua (eplontersen) failed to meet its primary endpoint in a late-stage study targeting transthyretin amyloid cardiomyopathy (ATTR-CM). This has boosted Alnylam's management's confidence in the prospects for nucresiran, a drug it's evaluating in Phase 3 studies for the treatment of ATTR-CM and hereditary ATTR amyloidosis with polyneuropathy (ATTR-PN).

Alnylam's pipeline is chock-full of other promising programs, too. Most of them are fully owned or have company-led development, although some candidates are out-licensed to partners.

Premium Feature

Moneyball Superscore

81/100

Today's Change

(

2.55

%) $

6.37

Current Price

$

255.96

Two things to watch Could Wall Street analysts and I be wrong about Alnylam? I don't think so, but there are a couple of things to watch that could change the narrative about the stock.

First, Alnylam cut its full-year revenue guidance after management saw that early demand growth for Amvuttra in treating ATTR-CM "benefited significantly from pent-up demand for a new therapy that has since normalized." If the company's results for the third and fourth quarters of 2026 don't show that this demand normalization is truly only a temporary issue, it wouldn't be surprising if some analysts downgraded the stock.

Second, it's possible that AstraZeneca and Ionis could release more details from the Wainua trial that increase concerns about Alnylam's prospects for nucresiran. I don't expect that to happen, but I wouldn't rule it out.

Barring negative developments on these fronts, though, I think Wall Street is right to be bullish about Alnylam. And the consensus 12-month price target upside of roughly 44% is attainable, in my view.

Keith Speights has positions in Pfizer. The Motley Fool has positions in and recommends Alnylam Pharmaceuticals, AstraZeneca Plc, Ionis Pharmaceuticals, and Pfizer. The Motley Fool has a disclosure policy.

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Get Free Report) has been assigned an average recommendation of “Moderate Buy” from the twenty-three research firms that are presently covering the stock, Marketbeat reports. Five research analysts have rated the stock with a hold rating, sixteen have issued a buy rating and two have assigned a strong buy rating to the company. The average 12 month price target among brokers that have issued ratings on the stock in the last year is $367.20.

ALNY has been the subject of several recent analyst reports. Morgan Stanley lowered their price target on Alnylam Pharmaceuticals from $400.00 to $300.00 and set an “equal weight” rating for the company in a report on Friday, July 31st. Citigroup reduced their price target on shares of Alnylam Pharmaceuticals from $380.00 to $340.00 and set a “buy” rating for the company in a report on Monday, August 3rd. Royal Bank Of Canada decreased their price objective on Alnylam Pharmaceuticals from $445.00 to $350.00 and set an “outperform” rating for the company in a report on Friday, July 31st. Wells Fargo & Company lowered their price target on shares of Alnylam Pharmaceuticals from $316.00 to $256.00 and set an “equal weight” rating on the stock in a research note on Friday, August 14th. Finally, Jefferies Financial Group upped their price objective on Alnylam Pharmaceuticals from $230.00 to $260.00 and gave the stock a “hold” rating in a research note on Tuesday, September 8th.

Read Our Latest Stock Analysis on ALNY

Hedge Funds Weigh In On Alnylam Pharmaceuticals Several institutional investors and hedge funds have recently modified their holdings of the business. MV Capital Management Inc. acquired a new stake in shares of Alnylam Pharmaceuticals in the 4th quarter valued at $25,000. Manchester Capital Management LLC raised its holdings in Alnylam Pharmaceuticals by 600.0% in the 4th quarter. Manchester Capital Management LLC now owns 84 shares of the biopharmaceutical company’s stock valued at $33,000 after buying an additional 72 shares during the last quarter. Leonteq Securities AG acquired a new position in shares of Alnylam Pharmaceuticals during the fourth quarter worth $42,000. Titan Wealth CI Ltd acquired a new position in Alnylam Pharmaceuticals during the 4th quarter worth about $42,000. Finally, SHP Wealth Management bought a new stake in Alnylam Pharmaceuticals in the fourth quarter valued at approximately $43,000. 92.97% of the stock is currently owned by institutional investors and hedge funds. Alnylam Pharmaceuticals Stock Up 2.0% Shares of NASDAQ:ALNY opened at $244.32 on Tuesday. The company has a 50 day moving average price of $246.41 and a two-hundred day moving average price of $285.10. The company has a debt-to-equity ratio of 0.75, a quick ratio of 2.99 and a current ratio of 3.05. The company has a market capitalization of $32.69 billion, a PE ratio of 45.41 and a beta of 0.31. Alnylam Pharmaceuticals has a 52 week low of $197.81 and a 52 week high of $495.55.

Alnylam Pharmaceuticals (NASDAQ:ALNY – Get Free Report) last announced its quarterly earnings results on Thursday, July 30th. The biopharmaceutical company reported $1.84 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.63 by $0.21. The company had revenue of $1.29 billion during the quarter, compared to analyst estimates of $1.32 billion. Alnylam Pharmaceuticals had a net margin of 15.26% and a return on equity of 84.93%. The firm’s revenue was up 66.9% on a year-over-year basis. During the same quarter in the previous year, the business earned ($0.51) EPS. Analysts forecast that Alnylam Pharmaceuticals will post 6.71 earnings per share for the current year.

Alnylam Pharmaceuticals Company Profile (Get Free Report)

Alnylam Pharmaceuticals, Inc is a biopharmaceutical company focused on discovering, developing and commercializing medicines based on RNA interference (RNAi) technology. RNAi therapies are designed to silence specific genes involved in disease, offering a way to target conditions that may be difficult to treat with conventional drug approaches. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.

Alnylam’s commercial products include Onpattro (patisiran), Givlaari (givosiran), Oxlumo (lumasiran) and Amvuttra (vutrisiran).

See Also Five stocks we like better than Alnylam Pharmaceuticals Can Bloom Energy Pop the Top Off AI’s Massive Energy Bottleneck? Coach’s Momentum Powers Tapestry Despite the Stock’s Sharp Pullback AI Is Reshaping SaaS—These 2 Software ETFs Offer Different Ways to Play It Insiders Signal Deep Value In DICK’s Sporting Goods

Receive News & Ratings for Alnylam Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Alnylam Pharmaceuticals (NASDAQ:ALNY) highlighted continued momentum for its AMVUTTRA treatment in transthyretin-mediated cardiomyopathy, while outlining a pipeline of upcoming clinical catalysts and discussing changes in the market that prompted a revision to its 2026 TTR franchise revenue outlook.

Speaking at the Morgan Stanley Global Healthcare Conference, Chief Executive Officer Yvonne Greenstreet said Alnylam’s TTR franchise generated more than $1 billion in revenue during the second quarter. The company received its cardiomyopathy indication for AMVUTTRA in March 2025.

Greenstreet attributed the launch performance to data from the HELIOS-B study, access initiatives and physician adoption. She said the study produced results on all-cause mortality across patient subgroups, including patients using stabilizers and those not receiving stabilizers. Alnylam has also continued to generate analyses of cardiac structure and function and extracardiac manifestations, she said. AMVUTTRA’s quarterly subcutaneous dosing also supports adherence, Greenstreet said. She added that most patients can obtain the drug with no out-of-pocket cost, while 90% can access treatment within 10 miles of home. Alnylam has more than 50% market share among physicians who have used AMVUTTRA, according to Greenstreet.

Guidance Reset Reflects Second-Line Demand Alnylam revised its 2026 TTR franchise revenue guidance to a range of $4.2 billion to $4.5 billion, representing a $200 million reduction at the midpoint. Greenstreet said the revision reflected a better understanding of how second-line demand has evolved.

At the 2025 launch, the company saw pent-up demand from patients who were progressing on existing treatments and awaiting a new option. The company’s business was then approximately balanced between first-line and second-line use. In 2026, that mix has moved toward what Greenstreet described as the broader market’s composition: roughly 80% first-line and 20% second-line.

Despite the revised outlook, Greenstreet said market fundamentals remain strong. She cited an estimated 200,000 TTR cardiomyopathy patients in the U.S. and 500,000 globally, with approximately 80% of patients still undiagnosed and untreated.

John Kennedy, senior vice president of global commercialization and lead of the TTR franchise, said Alnylam expects modest, gradual net-price reductions over time as volume and experience build. On a proposed change involving the 340B program, Kennedy said the outcome remains uncertain following the comment period, though historically proposed rule changes are generally concluded in November.

Kennedy said Alnylam has developed alternate sites of care to preserve patient access and offer providers options. Greenstreet said the company’s priority is ensuring patients who need AMVUTTRA can obtain it.

Company Sees HELIOS-B as Distinct From CARDIO-TTRansform Greenstreet addressed questions surrounding results from the CARDIO-TTRansform study of eplontersen, saying the trial’s outcome reflected several factors, including the degree of TTR knockdown, enrolled patient population and endpoint selection.

She noted that eplontersen achieved less than 70% mean TTR knockdown in that study, compared with 81% mean knockdown for AMVUTTRA in HELIOS-B. Greenstreet said the difference was meaningful and suggested the collective evidence could indicate a relationship between deeper TTR knockdown and better outcomes in TTR cardiomyopathy.

She also pointed to the importance of treating patients earlier in their disease course and using endpoints that capture the multisystem nature of TTR cardiomyopathy. Kennedy said a survey of cardiologists conducted after the initial announcement of the CARDIO-TTRansform outcome found that physicians overwhelmingly did not expect to change their current behavior or their view of silencing therapies.

Alnylam is continuing enrollment in its TRITON-CM study of nucresiran, which Greenstreet said has shown 95% TTR knockdown. The company is considering whether changes to patient enrollment, including potential enrichment or a larger study, may be appropriate. If it makes enrollment-related changes, Alnylam would disclose them before year-end, she said. Changes to the statistical analysis plan could be made later in the study.

Greenstreet also said Alnylam now expects generic tafamidis to become available in 2031 rather than 2028. She said that timing should reduce near-term pricing pressure and give AMVUTTRA more time to become established as a foundational therapy.

Pipeline Catalysts Ahead Greenstreet identified several pipeline programs expected to produce updates later in the year. Alnylam plans to report Phase I data in October for its Huntington’s disease program, which is designed to address both full-length huntingtin and the exon 1 fragment. The company expects to assess safety, tolerability, pharmacokinetics and pharmacodynamics, including huntingtin lowering in cerebrospinal fluid.

The company is also advancing ALN-6400, a plasminogen-targeting program for bleeding disorders. A Phase II study in hereditary hemorrhagic telangiectasia is evaluating bleeding frequency and severity in patients who may experience severe nosebleeds, gastrointestinal bleeding, anemia and transfusion requirements. Alnylam is also developing the program in von Willebrand disease.

In obesity, Greenstreet said Alnylam expects proof-of-concept data later this year aimed at demonstrating delivery of siRNA into adipose tissue. The company is evaluating potential obesity applications as monotherapy and in combinations with other siRNA medicines or incretin therapies.

For zilebesiran, Alnylam is conducting a large outcomes study in hypertension. Greenstreet said the company believes infrequent subcutaneous dosing could support more continuous blood-pressure control and address medication adherence challenges.

Finally, Greenstreet said Alnylam is using artificial intelligence across its operations and has entered an agreement with Inceptive Nucleics to combine the partner’s frontier models with Alnylam’s siRNA data in an effort to accelerate innovation.

About Alnylam Pharmaceuticals (NASDAQ:ALNY) Alnylam Pharmaceuticals, Inc is a biopharmaceutical company focused on discovering, developing and commercializing medicines based on RNA interference (RNAi) technology. RNAi therapies are designed to silence specific genes involved in disease, offering a way to target conditions that may be difficult to treat with conventional drug approaches. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.

Alnylam’s commercial products include Onpattro (patisiran), Givlaari (givosiran), Oxlumo (lumasiran) and Amvuttra (vutrisiran).

The Phase 3 Failure That Sent Biotech Winners and Losers in Opposite DirectionsAlnylam Pharmaceuticals NASDAQ: ALNY highlighted continued momentum for its AMVUTTRA treatment in transthyretin-mediated cardiomyopathy, while outlining a pipeline of upcoming clinical catalysts and discussing changes in the market that prompted a revision to its 2026 TTR franchise revenue outlook.

Speaking at the Morgan Stanley Global Healthcare Conference, Chief Executive Officer Yvonne Greenstreet said Alnylam’s TTR franchise generated more than $1 billion in revenue during the second quarter. The company received its cardiomyopathy indication for AMVUTTRA in March 2025.

Get ALNY alerts:

Alnylam Stock Soars 65%: Find Out What’s Behind the GainsGreenstreet attributed the launch performance to data from the HELIOS-B study, access initiatives and physician adoption. She said the study produced results on all-cause mortality across patient subgroups, including patients using stabilizers and those not receiving stabilizers. Alnylam has also continued to generate analyses of cardiac structure and function and extracardiac manifestations, she said.

AMVUTTRA’s quarterly subcutaneous dosing also supports adherence, Greenstreet said. She added that most patients can obtain the drug with no out-of-pocket cost, while 90% can access treatment within 10 miles of home. Alnylam has more than 50% market share among physicians who have used AMVUTTRA, according to Greenstreet.

Guidance Reset Reflects Second-Line Demand 3 biotech powerhouses poised to thrive amid sector reboundAlnylam revised its 2026 TTR franchise revenue guidance to a range of $4.2 billion to $4.5 billion, representing a $200 million reduction at the midpoint. Greenstreet said the revision reflected a better understanding of how second-line demand has evolved.

At the 2025 launch, the company saw pent-up demand from patients who were progressing on existing treatments and awaiting a new option. The company’s business was then approximately balanced between first-line and second-line use. In 2026, that mix has moved toward what Greenstreet described as the broader market’s composition: roughly 80% first-line and 20% second-line.

Despite the revised outlook, Greenstreet said market fundamentals remain strong. She cited an estimated 200,000 TTR cardiomyopathy patients in the U.S. and 500,000 globally, with approximately 80% of patients still undiagnosed and untreated.

John Kennedy, senior vice president of global commercialization and lead of the TTR franchise, said Alnylam expects modest, gradual net-price reductions over time as volume and experience build. On a proposed change involving the 340B program, Kennedy said the outcome remains uncertain following the comment period, though historically proposed rule changes are generally concluded in November.

Kennedy said Alnylam has developed alternate sites of care to preserve patient access and offer providers options. Greenstreet said the company’s priority is ensuring patients who need AMVUTTRA can obtain it.

Company Sees HELIOS-B as Distinct From CARDIO-TTRansform Greenstreet addressed questions surrounding results from the CARDIO-TTRansform study of eplontersen, saying the trial’s outcome reflected several factors, including the degree of TTR knockdown, enrolled patient population and endpoint selection.

She noted that eplontersen achieved less than 70% mean TTR knockdown in that study, compared with 81% mean knockdown for AMVUTTRA in HELIOS-B. Greenstreet said the difference was meaningful and suggested the collective evidence could indicate a relationship between deeper TTR knockdown and better outcomes in TTR cardiomyopathy.

She also pointed to the importance of treating patients earlier in their disease course and using endpoints that capture the multisystem nature of TTR cardiomyopathy. Kennedy said a survey of cardiologists conducted after the initial announcement of the CARDIO-TTRansform outcome found that physicians overwhelmingly did not expect to change their current behavior or their view of silencing therapies.

Alnylam is continuing enrollment in its TRITON-CM study of nucresiran, which Greenstreet said has shown 95% TTR knockdown. The company is considering whether changes to patient enrollment, including potential enrichment or a larger study, may be appropriate. If it makes enrollment-related changes, Alnylam would disclose them before year-end, she said. Changes to the statistical analysis plan could be made later in the study.

Greenstreet also said Alnylam now expects generic tafamidis to become available in 2031 rather than 2028. She said that timing should reduce near-term pricing pressure and give AMVUTTRA more time to become established as a foundational therapy.

Pipeline Catalysts Ahead Greenstreet identified several pipeline programs expected to produce updates later in the year. Alnylam plans to report Phase I data in October for its Huntington’s disease program, which is designed to address both full-length huntingtin and the exon 1 fragment. The company expects to assess safety, tolerability, pharmacokinetics and pharmacodynamics, including huntingtin lowering in cerebrospinal fluid.

The company is also advancing ALN-6400, a plasminogen-targeting program for bleeding disorders. A Phase II study in hereditary hemorrhagic telangiectasia is evaluating bleeding frequency and severity in patients who may experience severe nosebleeds, gastrointestinal bleeding, anemia and transfusion requirements. Alnylam is also developing the program in von Willebrand disease.

In obesity, Greenstreet said Alnylam expects proof-of-concept data later this year aimed at demonstrating delivery of siRNA into adipose tissue. The company is evaluating potential obesity applications as monotherapy and in combinations with other siRNA medicines or incretin therapies.

For zilebesiran, Alnylam is conducting a large outcomes study in hypertension. Greenstreet said the company believes infrequent subcutaneous dosing could support more continuous blood-pressure control and address medication adherence challenges.

Finally, Greenstreet said Alnylam is using artificial intelligence across its operations and has entered an agreement with Inceptive Nucleics to combine the partner’s frontier models with Alnylam’s siRNA data in an effort to accelerate innovation.

About Alnylam Pharmaceuticals (NASDAQ:ALNY)Alnylam Pharmaceuticals, Inc is a biopharmaceutical company focused on discovering, developing and commercializing medicines based on RNA interference (RNAi) technology. RNAi therapies are designed to silence specific genes involved in disease, offering a way to target conditions that may be difficult to treat with conventional drug approaches. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.

Alnylam's commercial products include Onpattro (patisiran), Givlaari (givosiran), Oxlumo (lumasiran) and Amvuttra (vutrisiran).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected].

Should You Invest $1,000 in Alnylam Pharmaceuticals Right Now?Before you consider Alnylam Pharmaceuticals, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Alnylam Pharmaceuticals wasn't on the list.

While Alnylam Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Kelly Cronin

Good morning, everyone. I'm Kelly Cronin, Senior Manager of Investor Relations at Alnylam, and I'm pleased to welcome you to the second event of Alnylam's 10th RNAi Roundtable series. Through this series, we aim to bring greater visibility to select near- and midterm pipeline programs that we believe will define the next wave of transformative medicines emerging from our RNAi platform here at Alnylam.

Today's event is focused on zilebesiran, our investigational RNAi therapeutic for patients with hypertension and high cardiovascular risk or established cardiovascular disease, which we are advancing together with our partners at Roche.

As a reminder, today's discussion will include forward-looking statements. We encourage you to review our most recent SEC filings for a more complete discussion of our risk factors. During today's event, you'll hear first from Chief Research and Development Officer, Pushkal Garg, who will set the stage with an overview of Alnylam's organic product engine and the unique potential of RNAi therapeutics to transform cardiovascular care.

Dr. Akshay Desai, of Harvard Medical School and Mass General Brigham, will then discuss the persistent burden of hypertension beyond the office setting followed by Ishir Bhan, who will review clinical evidence supporting the potential for continuous control with zilebesiran.

Simon Fox will then close out our prepared remarks with an overview of the integrated execution underway to realize zilebesiran's full potential. Following the prepared remarks, we will open the discussion for a question-and-answer session with our

Arizona State Retirement System grew its stake in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Free Report) by 5.9% in the second quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 38,025 shares of the biopharmaceutical company’s stock after acquiring an additional 2,126 shares during the period. Arizona State Retirement System’s holdings in Alnylam Pharmaceuticals were worth $11,447,000 at the end of the most recent reporting period.

Several other large investors have also recently modified their holdings of ALNY. MV Capital Management Inc. bought a new stake in Alnylam Pharmaceuticals during the 4th quarter valued at $25,000. HM Payson & Co. bought a new stake in Alnylam Pharmaceuticals during the 4th quarter worth approximately $27,000. Golden State Wealth Management LLC lifted its stake in Alnylam Pharmaceuticals by 100.0% in the 4th quarter. Golden State Wealth Management LLC now owns 72 shares of the biopharmaceutical company’s stock worth $29,000 after purchasing an additional 36 shares in the last quarter. Caitong International Asset Management Co. Ltd purchased a new stake in Alnylam Pharmaceuticals in the 3rd quarter worth approximately $29,000. Finally, Manchester Capital Management LLC boosted its holdings in Alnylam Pharmaceuticals by 600.0% in the 4th quarter. Manchester Capital Management LLC now owns 84 shares of the biopharmaceutical company’s stock valued at $33,000 after purchasing an additional 72 shares during the period. Hedge funds and other institutional investors own 92.97% of the company’s stock.

Shares of NASDAQ:ALNY opened at $258.00 on Thursday. The stock has a market capitalization of $34.52 billion, a P/E ratio of 47.96 and a beta of 0.31. The stock’s 50-day moving average price is $257.01 and its 200-day moving average price is $289.90. The company has a current ratio of 3.05, a quick ratio of 2.99 and a debt-to-equity ratio of 0.75. Alnylam Pharmaceuticals, Inc. has a 12-month low of $197.81 and a 12-month high of $495.55.

Alnylam Pharmaceuticals (NASDAQ:ALNY – Get Free Report) last released its earnings results on Thursday, July 30th. The biopharmaceutical company reported $1.84 earnings per share for the quarter, beating analysts’ consensus estimates of $1.63 by $0.21. The company had revenue of $1.29 billion during the quarter, compared to analyst estimates of $1.32 billion. Alnylam Pharmaceuticals had a return on equity of 84.93% and a net margin of 15.26%.Alnylam Pharmaceuticals’s revenue for the quarter was up 66.9% on a year-over-year basis. During the same quarter in the previous year, the company posted ($0.51) EPS. On average, equities analysts anticipate that Alnylam Pharmaceuticals, Inc. will post 6.71 earnings per share for the current year. Analyst Ratings Changes Several research analysts recently weighed in on ALNY shares. Barclays decreased their price objective on shares of Alnylam Pharmaceuticals from $527.00 to $450.00 and set an “overweight” rating on the stock in a research report on Monday, August 3rd. Needham & Company LLC cut their price target on shares of Alnylam Pharmaceuticals from $510.00 to $357.00 and set a “buy” rating for the company in a research note on Thursday, July 30th. Raymond James Financial raised shares of Alnylam Pharmaceuticals from an “outperform” rating to a “strong-buy” rating and set a $420.00 price target on the stock in a report on Monday, August 3rd. HC Wainwright restated a “buy” rating and set a $455.00 price objective on shares of Alnylam Pharmaceuticals in a research report on Wednesday, September 2nd. Finally, Jefferies Financial Group upped their target price on shares of Alnylam Pharmaceuticals from $230.00 to $260.00 and gave the stock a “hold” rating in a research report on Tuesday. Two equities research analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and five have given a Hold rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $382.96.

Get Our Latest Report on ALNY

About Alnylam Pharmaceuticals (Free Report)

Alnylam Pharmaceuticals, Inc is a biopharmaceutical company focused on discovering, developing and commercializing medicines based on RNA interference (RNAi) technology. RNAi therapies are designed to silence specific genes involved in disease, offering a way to target conditions that may be difficult to treat with conventional drug approaches. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.

Alnylam’s commercial products include Onpattro (patisiran), Givlaari (givosiran), Oxlumo (lumasiran) and Amvuttra (vutrisiran).

Featured Articles Five stocks we like better than Alnylam Pharmaceuticals Qualcomm’s Data Center Bet Looks More Real After Amazon’s AI Deal GE Aerospace’s $11.75B Deal Puts Howmet Aerospace in Focus Casey’s Post-Earnings Drop May Give Investors a Better Entry Into a Quality Retailer Sovereign AI: Palantir and Nebius Cut the Cloud Cord

Receive News & Ratings for Alnylam Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Alnylam Pharmaceuticals, Inc. (ALNY) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript

NEW YORK, Aug. 26, 2026 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP continues its investigation on behalf of Alnylam Pharmaceuticals, Inc. (“Alnylam” or the “Company”) (NASDAQ: ALNY) investors concerning the Company’s and/or members of its senior management’s possible violation of the federal securities laws and other unlawful business practices.

[CONTACT THE FIRM IF YOU SUFFERED A LOSS]

What Happened?

On July 30, 2026, Alnylam announced second quarter 2026 financial results. Among other things, the Company reported it has “lowered our TTR product sales guidance for full-year 2026 to reflect learnings from the initial phase of our launch in the evolving ATTR-CM market, in particular the normalization of growth in second line volume after satisfying pent-up demand from patients waiting for a new therapy.” As a result, the Company lowered its total projected TTR net product revenues by approximately $200 million.

On this news, shares of Alnylam fell $81.14 per share, or approximately 28%, to close at on $205.48 per share July 30, 2026.

What Should I Do?

At this stage, no lawsuit has been filed. The investigation is ongoing to determine whether claims may be brought under federal securities laws.

If you purchased or otherwise acquired Alnylam securities, have information, or would like to learn more about this investigation, please contact Lauren Molinaro of Kirby McInerney LLP by email at [email protected], or fill out the contact form below, to discuss your rights or interests with respect to these matters at no cost.

[LEARN MORE ABOUT SECURITIES CLASS ACTIONS]

Kirby McInerney LLP is a New York-based plaintiffs’ law firm concentrating in securities, antitrust, whistleblower, and consumer litigation. The firm’s efforts on behalf of shareholders in securities litigation have resulted in recoveries totaling billions of dollars. Additional information about the firm can be found at Kirby McInerney LLP’s website.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contacts
Kirby McInerney LLP        
Lauren Molinaro, Esq.
212-699-1171
https://www.kmllp.com
https://securitiesleadplaintiff.com/
[email protected]

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced new data at the European Society of Cardiology (ESC) Congress 2026 demonstrating the strength of RNAi-powered silencing for cardiovascular disease. The findings further reinforce the clinical profile of AMVUTTRA® (vutrisiran) across transthyretin amyloidosis (ATTR) patient populations, treatment settings, and manifestations of disease. Additionally, the data expand the potential application of RNAi to uncontrolled hypertension, the world’s leading cause of cardiovascular disease.

“With the power of our RNAi therapeutics platform, we have the potential to make a transformational impact on cardiovascular care,” said Pushkal Garg, M.D., Chief Research and Development Officer at Alnylam. “The data presented at ESC demonstrate the consistency of clinical outcomes achieved by RNAi-powered TTR silencing, reinforcing our conviction in AMVUTTRA as a first-line treatment option for ATTR-CM. With zilebesiran, we have the potential to extend the precision and durability of RNAi to uncontrolled hypertension. Together, these programs reflect our ambition to change the course of cardiovascular disease for patients with high unmet need.”

Vutrisiran Analyses

HELIOS-B Prespecified Subgroup Analysis Demonstrates Consistent Clinical Benefit with Vutrisiran Across Contemporary ATTR-CM Treatment Settings

A late-breaking oral presentation featured a prespecified subgroup analysis of the HELIOS-B Phase 3 clinical trial evaluating the treatment effect of vutrisiran according to baseline tafamidis use. The results were simultaneously published in the Journal of the American College of Cardiology.

Among 654 randomized and treated patients in HELIOS-B, 259 patients (40%) were receiving tafamidis at baseline. The treatment effect for vutrisiran on the primary composite endpoint of all-cause mortality and recurrent cardiovascular events through 33-36 months was consistent irrespective of baseline tafamidis use, suggesting clinical benefits across broad patient populations, including those receiving stabilizers.

All-cause mortality and additional cardiovascular outcomes showed a similar benefit among patients who were receiving tafamidis at baseline (“combination population”) and those who were not (“monotherapy population”). Across both groups, treatment with vutrisiran preserved functional capacity versus placebo, as measured by the Six-Minute Walk Test. Improvement in health status by vutrisiran versus placebo, as measured by the Kansas City Cardiomyopathy Questionnaire-overall summary score, was observed in both the monotherapy and combination populations with an attenuated effect seen among patients receiving tafamidis at baseline. Safety outcomes were generally similar between combination vutrisiran and tafamidis versus tafamidis alone, and between vutrisiran monotherapy versus placebo. HELIOS-B was not powered to establish the benefit of vutrisiran specifically in the population of patients receiving background tafamidis at baseline. These findings reinforce the impact of vutrisiran across contemporary ATTR-CM treatment settings and warrant further evaluation of TTR silencing and stabilization combination strategies.

Additional HELIOS-B Analyses Highlight the Potential Impact of Vutrisiran on the Multisystemic Burden of ATTR-CM

Additional analyses presented at ESC further underscore the multisystemic burden of ATTR-CM and the importance of evaluating measures beyond traditional cardiac endpoints. Real-world evidence from the French National Health Data System showed that patients with ATTR-CM had a significantly higher burden of extra-cardiac manifestations across multiple organ systems compared with matched controls, and multiple manifestations were recorded years before ATTR-CM identification and tended to accumulate over time, suggesting a prolonged pre-diagnostic phase with evolving multisystem involvement.

A post hoc analysis of HELIOS-B evaluated the impact of treatment with vutrisiran on intrinsic capacity, a composite measure encompassing locomotion, cognition, vitality, psychological well-being and sensory function aligned with the World Health Organization Integrated Care for Older People framework. In the overall study population, compared with placebo, patients treated with vutrisiran demonstrated 25% less decline from baseline intrinsic capacity score and a 52% reduction in the risk of decline, suggesting that treatment with vutrisiran may help preserve functional reserve and support healthy aging in patients with ATTR-CM.

A separate post hoc safety analysis of HELIOS-B showed that patients treated with vutrisiran had fewer adverse events overall compared with placebo across the overall study population, monotherapy population and combination population. Among the most frequent system organ classes in the overall population, the lowest adverse event rate ratios were observed for gastrointestinal disorders and nervous system disorders, with 42% and 41% lower adverse event rates, respectively, with vutrisiran compared with placebo; eye disorders showed a 46% lower event rate with vutrisiran compared with placebo.

Pooled Phase 3 Data Reinforce Consistent Treatment Effects of RNAi-Powered TTR Silencing Across Sexes

A pooled analysis of 1,402 patients (203 females, 1,199 males) across four Phase 3 studies of vutrisiran and patisiran further reinforces the clinical benefits of RNAi-mediated TTR silencing across sexes. Despite sex-specific baseline differences in disease presentation, treatment effects were consistent between females and males across both ATTR-CM and the polyneuropathy of hereditary ATTR (hATTR-PN), including clinical, biomarker, functional, health status and echocardiographic measures.

“These data add to the deep and consistent evidence base supporting RNAi-mediated TTR silencing in ATTR-CM,” said Teresa Trenkwalder, M.D., Senior Physician, TUM University Hospital German Heart Center. “Across patient populations, treatment settings, and manifestations of disease, the analyses of vutrisiran demonstrate the clinical benefit that can be achieved by reducing TTR production at its source.”

Zilebesiran Analysis

The KARDIA-3 Phase 2 study evaluated zilebesiran, an investigational RNAi therapeutic with the potential to provide continuous control of blood pressure (BP) with biannual dosing, in patients with uncontrolled hypertension with high cardiovascular (CV) risk treated with two or more background antihypertensives. In patients who were receiving a background diuretic with an office systolic BP (SBP) ≥140 mmHg at baseline, zilebesiran achieved greater reductions in mean office and 24-hour ambulatory SBP than in the overall study population. Furthermore, patients treated with zilebesiran experienced SBP reductions across the diurnal cycle, including at nighttime. Similar findings were observed in patients who had impaired nocturnal dipping at baseline. These findings are potentially important given the association between elevated nighttime BP and CV risk. The safety profile in this post hoc subgroup was consistent with the broader zilebesiran Phase 2 program. These findings further support the evaluation of zilebesiran in the ongoing global Phase 3 CV outcomes trial, ZENITH.

Zilebesiran will be featured as part of Alnylam's 10th “RNAi Roundtable” series on September 17, 2026, at 10:30 a.m. ET.

To view Alnylam’s ESC Congress 2026 presentations, please visit Capella. Alnylam may share additional data and information during the Congress through its Investors website and/or Capella.

AMVUTTRA® (vutrisiran) INDICATIONS AND IMPORTANT SAFETY INFORMATION

Indications

In the EU, AMVUTTRA® (vutrisiran) is indicated for the treatment of:

hereditary transthyretin amyloidosis in adult patients with stage 1 or stage 2 polyneuropathy (hATTR-PN).wild-type or hereditary transthyretin amyloidosis in adult patients with cardiomyopathy (ATTR-CM).Availability across the EU is subject to local reimbursement timelines.

Important Safety Information

Reduced Serum Vitamin A Levels and Recommended Supplementation

Vutrisiran treatment can lower serum vitamin A levels, therefore supplementation of approximately, but not exceeding, 2500 IU to 3000 IU vitamin A per day is advised for patients.

Adverse Reactions

Commonly reported adverse reactions with vutrisiran were injection site reactions and increase in blood alkaline phosphatase and alanine transaminase.

For additional information about vutrisiran, please see the full Summary of Product Characteristics.

ONPATTRO® (patisiran) INDICATION AND IMPORTANT SAFETY INFORMATION

Indication

In the EU, ONPATTRO® (patisiran) is indicated for the treatment of hereditary transthyretin-mediated (hATTR) amyloidosis in adults with stage 1 or stage 2 polyneuropathy.

Important Safety Information

Reduced Serum Vitamin A Levels and Recommended Supplementation

Patisiran treatment can lower serum vitamin A levels, therefore supplementation of approximately, but not exceeding, 2500 IU to 3000 IU vitamin A per day is advised for patients.

Adverse Reactions

The most common adverse reactions that occurred in patients treated with patisiran were peripheral oedema (30%) and infusion-related reactions (19%).

For additional information about patisiran, please see the full Summary of Product Characteristics

About AMVUTTRA® (vutrisiran)

AMVUTTRA® (vutrisiran) demonstrates strength in RNAi-powered transthyretin (TTR) silencing, delivering rapid knockdown of TTR at the source of disease to address the underlying cause of transthyretin amyloidosis (ATTR). In the HELIOS-B Phase 3 study, AMVUTTRA reduced the risk of all-cause mortality and recurrent CV events compared to placebo in the overall and monotherapy populations by 28.2% and 32.8%, respectively, through 36 months. It is the only TTR silencer approved for both the polyneuropathy of hereditary transthyretin-mediated amyloidosis (hATTR-PN) and cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) in countries globally. AMVUTTRA is administered once quarterly via subcutaneous injection.

About Transthyretin Amyloidosis (ATTR)

Transthyretin amyloidosis (ATTR) is an underdiagnosed, rapidly progressive, debilitating, and fatal disease caused by pathogenic transthyretin (TTR) proteins, which accumulate as amyloid deposits in various parts of the body, including the nerves, heart, and gastrointestinal tract. Patients may present with polyneuropathy, cardiomyopathy, or both manifestations of disease. There are two different forms of ATTR – hereditary ATTR (hATTR), which is caused by a TTR gene variant, and wild-type ATTR (wtATTR), which occurs without a TTR gene variant. It is estimated that more than 500,000 people worldwide live with ATTR, with ~80% remaining undiagnosed.

About Zilebesiran

Zilebesiran is an investigational, subcutaneously administered RNAi therapeutic in development for cardiovascular (CV) risk reduction in hypertensive patients at high risk or with established CVD. Zilebesiran targets angiotensinogen (AGT), the most upstream precursor in the renin-angiotensin-aldosterone system (RAAS), which plays a role in blood pressure (BP) regulation and impacts CV and renal health. Clinical trial results have shown the potential for zilebesiran to provide continuous control of BP with biannual dosing in a broad population of patients with hypertension. Zilebesiran is being evaluated in a Phase 3 CV outcomes trial, ZENITH, which will assess its ability to reduce the risk of CV death, nonfatal myocardial infarction, nonfatal stroke, or heart failure events in patients with hypertension and established or at high risk of CVD, despite the use of at least two or more antihypertensives. The safety and efficacy of zilebesiran have not been established or evaluated by the FDA, EMA, or any other health authority. Zilebesiran is being co-developed and co-commercialized by Alnylam and Roche.

About Cardiovascular Disease and Hypertension

Cardiovascular disease (CVD) is a global health crisis and a leading cause of death worldwide, responsible for approximately 20 million deaths annually. Hypertension is the primary cause of and number one modifiable risk factor for CVD. An estimated one in three adults worldwide have hypertension, and despite wide availability of antihypertensives, up to 80% of all patients, and up to one-third of treated patients, do not reach and maintain blood pressure (BP) targets. Even when BP appears well-managed, continuous control of BP may remain suboptimal, leading to variability in BP during the 24-hour period and in the long-term, putting patients at greater risk of cardiovascular events and end organ damage.

About RNAi

RNAi (RNA interference) is a natural cellular process of gene silencing that represents one of the most promising and rapidly advancing frontiers in biology and drug development today. Its discovery has been heralded as “a major scientific breakthrough that happens once every decade or so,” and was recognized with the award of the 2006 Nobel Prize for Physiology or Medicine. By harnessing the natural biological process of RNAi occurring in our cells, a new class of medicines known as RNAi therapeutics is now a reality. Small interfering RNA (siRNA), the molecules that mediate RNAi and comprise Alnylam’s RNAi therapeutic platform, function upstream of today’s medicines by potently silencing messenger RNA (mRNA) – the genetic precursors – that encode for disease-causing or disease pathway proteins, thus preventing them from being made. This is a revolutionary approach with the potential to transform the care of patients with genetic and other diseases.

About Alnylam Pharmaceuticals

Alnylam (Nasdaq: ALNY) is a leading global biopharmaceutical company and the pioneer of the RNA interference (RNAi) revolution. The Company is focused on developing transformative therapies with the potential to prevent, halt, or reverse disease. For more than two decades, Alnylam has advanced the Nobel-Prize-winning science of RNAi, delivering critical breakthroughs and six approved medicines. Alnylam has medicines available in more than 70 countries and a rapidly expanding and robust pipeline, in addition to consistently being recognized as an exceptional workplace and socially responsible organization. The Company is executing on its Alnylam 2030 strategy to accelerate innovation and scale impact to transform human health. Alnylam routinely posts information that may be important to investors in the “Investors” section of its website at https://investors.alnylam.com/. Investors and potential investors are encouraged to consult the Alnylam website regularly.

Alnylam Forward-Looking Statements

This press release contains forward-looking statements. Forward-looking statements include statements regarding Alnylam’s expectations, beliefs, goals, plans or prospects including, without limitation, statements regarding the potential efficacy or safety of vutrisiran for the treatment of ATTR CM, including in combination with a stabilizer; the potential clinical benefit that can be achieved by reducing TTR production at its source across patient populations, treatment settings and manifestations of disease; the potential for AMVUTTRA to be a first-line treatment for ATTR-CM; the potential for zilebesiran to extend the precision and durability of RNAi, and to provide continuous control of blood pressure with biannual dosing, in patients with uncontrolled hypertension; Alnylam’s ability to make a transformational impact on cardiovascular care and to change the course of cardiovascular disease for patients with high unmet need; and Alnylam’s ability to execute on its Alnylam 2030 strategy to accelerate innovation and scale impact to transform human health. Actual results and future plans may differ materially from those indicated by these forward-looking statements as a result of various important risks, uncertainties and other factors, including, without limitation, risks and uncertainties relating to: Alnylam’s ability to successfully execute on its Alnylam 2030 strategy; Alnylam’s ability to successfully launch, market and sell Alnylam’s approved products globally, including AMVUTTRA; Alnylam’s ability to discover and develop novel drug candidates and delivery approaches and successfully demonstrate the efficacy and safety of its product candidates; the pre-clinical and clinical results for Alnylam’s product candidates; actions or advice of regulatory agencies and Alnylam’s ability to obtain and maintain regulatory approval for its product candidates, as well as favorable pricing and reimbursement; delays, interruptions or failures in the manufacture and supply of Alnylam’s marketed products or its product candidates; obtaining, maintaining and protecting intellectual property; Alnylam’s ability to manage its growth and operating expenses through disciplined investment in operations; Alnylam’s ability to maintain strategic business collaborations; Alnylam’s dependence on third parties for the development and commercialization of certain products; the outcome of litigation and government investigations; the risk of future litigation and government investigations; and unexpected expenditures; as well as those risks and uncertainties more fully discussed in the “Risk Factors” filed with Alnylam’s 2025 Annual Report on Form 10-K filed with the Securities and Exchange Commission (SEC), as may be updated from time to time in Alnylam’s subsequent Quarterly Reports on Form 10-Q, and in other filings that Alnylam makes with the SEC. Alnylam explicitly disclaims any obligation, except to the extent required by law, to update any forward-looking statements.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260829551848/en/

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that it will present new clinical and real-world data across its transthyretin-mediated amyloidosis (ATTR) and hypertension programs at the European Society of Cardiology (ESC) Congress 2026, taking place August 28-31, 2026, in Munich, Germany. These presentations add to the existing and growing body of evidence demonstrating strength in RNAi-powered transthyre.

, /PRNewswire/ -- Kessler Topaz Meltzer & Check, LLP (www.ktmc.com), a nationally recognized securities litigation law firm, is investigating potential violations of the federal securities laws by Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) on behalf of investors who purchased or acquired Alnylam Pharmaceuticals, Inc. securities and experienced significant financial losses.

Alnylam Reports Disappointing Financial Results
On July 30, 2026, Alnylam announced its second quarter 2026 financial results. Among other things, Alnylam reported that the company has "lowered our TTR product sales guidance for full-year 2026 to reflect learnings from the initial phase of our launch in the evolving ATTR-CM market, in particular the normalization of growth in second line volume after satisfying pent-up demand from patients waiting for a new therapy." As a result, Alnylam cut its total projected TTR net product revenues by approximately $200 million.

Alnylam's Stock Drops Over 28%
Following the news of Alnylam Pharmaceuticals, Inc.'s poor financial results, the company's stock price fell over 28%.

Investors who purchased Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) securities and experienced losses may have legal rights under the federal securities laws.

CONTACT KTMC TO DISCUSS YOUR LEGAL RIGHTS:
If you purchased or acquired Alnylam Pharmaceuticals, Inc. securities and have lost money on your investment, please provide your information here:
https://www.ktmc.com/alnylam-pharmaceuticals-inc-investigation?utm_campaign=hc?utm_source=PR_Newswire&utm_medium=pressrelease&utm_campaign=alny&mktm=PR

There is no cost or obligation to speak with an attorney.

ABOUT KESSLER TOPAZ MELTZER & CHECK, LLP (KTMC):
Kessler Topaz Meltzer & Check, LLP (KTMC) is a leading U.S. plaintiff-side law firm focused on securities-fraud class actions and global investor protection. The firm represents individual investors as well as institutions, such as major pension funds, asset managers, and international investors. KTMC has led some of the largest recoveries in securities litigation and has been recognized by peers and the legal media with numerous accolades, including being recognized in Chambers & Partners USA 2026 as a Band 1 Top Firm in Securities and Class Actions, Legal 500's Tier 1 Rankings for Securities and M&A Litigation, The National Law Journal's Plaintiff's Hot List and Trailblazers in Plaintiffs' Law, BTI Consulting Group's Honor Roll of Most Feared Law Firms, The Legal Intelligencer's Class Action Firm of the Year, Lawdragon's Leading Plaintiff Financial Lawyers, and Law360's Titans of the Plaintiffs Bar. The firm operates globally with offices in Pennsylvania and California. KTMC has recovered over $25 billion for our clients and the classes they represent.

CONTACT:
Jonathan Naji, Esq.
280 King of Prussia Road
Radnor, PA 19087
(484) 270-1453
[email protected]

May be considered attorney advertising in certain jurisdictions. Past results do not guarantee future outcomes.

SOURCE Kessler Topaz Meltzer & Check, LLP

If you purchased or acquired stock in Alnylam and would like to discuss your legal rights, contact Bragar Eagel & Squire partners Brandon Walker or Melissa Fortunato by email at [email protected] or by telephone at (212) 355-4648.

Click here to participate in the action.

NEW YORK, Aug. 20, 2026 (GLOBE NEWSWIRE) --

What’s Happening:

Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Alnylam Pharmaceuticals, Inc. (“Alnylam” or the “Company”) (NASDAQ:ALNY) on behalf of Alnylam stockholders. Our investigation concerns whether Alnylam has violated the federal securities laws and/or engaged in other unlawful business practices.
Investigation Details:

On July 30, 2026, Alnylam announced second-quarter 2026 financial results. Among other things, the Company reported it has "lowered our TTR product sales guidance for full-year 2026 to reflect learnings from the initial phase of our launch in the evolving ATTR-CM market, in particular the normalization of growth in second line volume after satisfying pent-up demand from patients waiting for a new therapy." As a result, Alnylam lowered its total projected TTR net product revenues by approximately $200 million. Following this news, Alnylam's stock price dropped as much as $81.25 per share, or 28.35%, during intraday trading on July 30, 2026.
Next Steps:

If you purchased or otherwise acquired Alnylam shares and suffered a loss, are a long-term stockholder, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Melissa Fortunato by email at [email protected], by telephone at (212) 355-4648, or by filling out this contact form. There is no cost or obligation to you.
About Bragar Eagel & Squire, P.C.:

Bragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York, South Carolina, and California. The firm represents individual and institutional investors in securities, derivative, and commercial litigation as well as individuals in consumer protection and data privacy litigation. The firm has a nationwide practice and routinely handles cases in both federal and state courts. For more information about the firm, please visit www.bespc.com. Attorney advertising. Prior results do not guarantee similar outcomes.

Follow us for updates on LinkedIn and Facebook, and keep up with other news by following Brandon Walker, Esq. on LinkedIn.

Contact Information:

Bragar Eagel & Squire, P.C.
Brandon Walker, Esq.
Melissa Fortunato, Esq.
(212) 355-4648
[email protected]
www.bespc.com

BENSALEM, Pa., Aug. 20, 2026 (GLOBE NEWSWIRE) -- Law Offices of Howard G. Smith continues its investigation on behalf of Alnylam Pharmaceuticals, Inc. (“Alnylam” or the “Company”) (NASDAQ: ALNY) investors concerning the Company’s possible violations of federal securities laws.

IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN ALNYLAM PHARMACEUTICALS, INC. (ALNY), CONTACT THE LAW OFFICES OF HOWARD G. SMITH ABOUT POTENTIALLY PURSUING CLAIMS TO RECOVER YOUR LOSS.

Contact the Law Offices of Howard G. Smith to discuss your legal rights by email at [email protected], by telephone at (215) 638-4847 or visit our website at www.howardsmithlaw.com.

What Happened?
On July 30, 2026, Alnylam announced second quarter 2026 financial results. Among other things, the Company reported it has “lowered our TTR product sales guidance for full-year 2026 to reflect learnings from the initial phase of our launch in the evolving ATTR-CM market, in particular the normalization of growth in second line volume after satisfying pent-up demand from patients waiting for a new therapy.” As a result, the Company lowered its total projected TTR net product revenues by approximately $200 million.

On this news, shares of Alnylam fell as much as $81.25 or 28.35% in intraday trading on July 30, 2026, thereby injuring investors.

Contact Us To Participate or Learn More:
If you purchased Alnylam Pharmaceuticals, Inc. securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact us:
Law Offices of Howard G. Smith,
3070 Bristol Pike, Suite 112,
Bensalem, Pennsylvania 19020,
Telephone: (215) 638-4847
Email: [email protected],
Visit our website at: www.howardsmithlaw.com.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contact Us:
Law Offices of Howard G. Smith
Howard G. Smith, Esquire
215-638-4847
[email protected]
www.howardsmithlaw.com

NEW YORK--(BUSINESS WIRE)---- $ALNY #ClassActionLawsuit--The law firm of Kirby McInerney LLP reminds investors of its investigation on behalf of Alnylam Pharmaceuticals, Inc. (“Alnylam” or the “Company”) (NASDAQ: ALNY) investors concerning the Company's and/or members of its senior management's possible violation of the federal securities laws or other unlawful business practices. [LEARN MORE ABOUT THE INVESTIGATION] What Happened? On July 30, 2026, Alnylam announced second quarter 2026 financial results. Among other things.

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.

BMO Capital analyst David Lebowitz initiated coverage on Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) with an Outperform rating and announced a price target of $318. Alnylam Pharmaceuticals closed at $228.61 on Tuesday. See how other analysts view this stock. Cantor Fitzgerald analyst Yanni Souroutzidis initiated coverage on Agomab Therapeutics NV (NASDAQ:AGMB) with an Overweight rating. AgomAb Therapeutics shares closed at $13.73 on Tuesday. See how other analysts view this stock. BMO Capital analyst David Lebowitz initiated coverage on Biomarin Pharmaceutical Inc (NASDAQ:BMRN) with an Outperform rating and announced a price target of $98. BioMarin Pharmaceutical closed at $66.99 on Tuesday. See how other analysts view this stock. CLSA analyst Alvin Huang initiated coverage on KE Holdings Inc – ADR (NYSE:BEKE) with an Outperform rating and announced a price target of $23.8. KE Holdings shares closed at $16.87 on Tuesday. See how other analysts view this stock. BMO Capital analyst David Lebowitz initiated coverage on Ionis Pharmaceuticals Inc (NASDAQ:IONS) with a Market Perform rating and announced a price target of $60. Ionis Pharmaceuticals closed at $59.62 on Tuesday. See how other analysts view this stock. Considering buying ALNY stock? Here’s what analysts think:

Photo via Shutterstock

Latest Private Market Opportunities

Join 400,000+ Investors

Market News and Data brought to you by Benzinga APIs

© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

To add Benzinga News as your preferred source on Google, click here.

, /PRNewswire/ -- Kessler Topaz Meltzer & Check, LLP (www.ktmc.com), a nationally recognized securities litigation law firm, is investigating potential violations of the federal securities laws by Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) on behalf of investors who purchased or acquired Alnylam Pharmaceuticals, Inc. securities and experienced significant financial losses.

Alnylam Reports Disappointing Financial Results
On July 30, 2026, Alnylam announced its second quarter 2026 financial results. Among other things, Alnylam reported that the company has "lowered our TTR product sales guidance for full-year 2026 to reflect learnings from the initial phase of our launch in the evolving ATTR-CM market, in particular the normalization of growth in second line volume after satisfying pent-up demand from patients waiting for a new therapy." As a result, Alnylam cut its total projected TTR net product revenues by approximately $200 million.

Alnylam's Stock Drops Over 28%
Following the news of Alnylam Pharmaceuticals, Inc.'s poor financial results, the company's stock price fell over 28%.

Investors who purchased Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) securities and experienced losses may have legal rights under the federal securities laws.

CONTACT KTMC TO DISCUSS YOUR LEGAL RIGHTS:
If you purchased or acquired Alnylam Pharmaceuticals, Inc. securities and have lost money on your investment, please provide your information here:

https://www.ktmc.com/alnylam-pharmaceuticals-inc-investigation?utm_campaign=hc?utm_source=PR_Newswire&utm_medium=pressrelease&utm_campaign=alny&mktm=PR

There is no cost or obligation to speak with an attorney.

ABOUT KESSLER TOPAZ MELTZER & CHECK, LLP (KTMC):
Kessler Topaz Meltzer & Check, LLP (KTMC) is a leading U.S. plaintiff-side law firm focused on securities-fraud class actions and global investor protection. The firm represents individual investors as well as institutions, such as major pension funds, asset managers, and international investors. KTMC has led some of the largest recoveries in securities litigation and has been recognized by peers and the legal media with numerous accolades, including being recognized in Chambers & Partners USA 2026 as a Band 1 Top Firm in Securities and Class Actions, Legal 500's Tier 1 Rankings for Securities and M&A Litigation, The National Law Journal's Plaintiff's Hot List and Trailblazers in Plaintiffs' Law, BTI Consulting Group's Honor Roll of Most Feared Law Firms, The Legal Intelligencer's Class Action Firm of the Year, Lawdragon's Leading Plaintiff Financial Lawyers, and Law360's Titans of the Plaintiffs Bar. The firm operates globally with offices in Pennsylvania and California. KTMC has recovered over $25 billion for our clients and the classes they represent.

CONTACT:
Jonathan Naji, Esq.
280 King of Prussia Road
Radnor, PA 19087
(484) 270-1453
[email protected]

May be considered attorney advertising in certain jurisdictions. Past results do not guarantee future outcomes.

SOURCE Kessler Topaz Meltzer & Check, LLP

RADNOR, Pa., Aug. 15, 2026 (GLOBE NEWSWIRE) -- Kessler Topaz Meltzer & Check, LLP (www.ktmc.com), a nationally recognized securities litigation law firm, is investigating potential violations of the federal securities laws by Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) on behalf of investors who purchased or acquired Alnylam Pharmaceuticals, Inc. securities and experienced significant financial losses.

Alnylam Reports Disappointing Financial Results
On July 30, 2026, Alnylam announced its second quarter 2026 financial results. Among other things, Alnylam reported that the company has “lowered our TTR product sales guidance for full-year 2026 to reflect learnings from the initial phase of our launch in the evolving ATTR-CM market, in particular the normalization of growth in second line volume after satisfying pent-up demand from patients waiting for a new therapy.” As a result, Alnylam cut its total projected TTR net product revenues by approximately $200 million.

Alnylam’s Stock Drops Over 28%
Following the news of Alnylam Pharmaceuticals, Inc.’s poor financial results, the company’s stock price fell over 28%.

Investors who purchased Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) securities and experienced losses may have legal rights under the federal securities laws.

CONTACT KTMC TO DISCUSS YOUR LEGAL RIGHTS:
If you purchased or acquired Alnylam Pharmaceuticals, Inc. securities and have lost money on your investment, please provide your information here:

https://www.ktmc.com/alnylam-pharmaceuticals-inc-investigation?utm_campaign=hc?utm_source=Globe&utm_medium=pressrelease&utm_campaign=alny&mktm=PR

There is no cost or obligation to speak with an attorney.

ABOUT KESSLER TOPAZ MELTZER & CHECK, LLP (KTMC):

Kessler Topaz Meltzer & Check, LLP (KTMC) is a leading U.S. plaintiff-side law firm focused on securities-fraud class actions and global investor protection. The firm represents individual investors as well as institutions, such as major pension funds, asset managers, and international investors. KTMC has led some of the largest recoveries in securities litigation and has been recognized by peers and the legal media with numerous accolades, including being recognized in Chambers & Partners USA 2026 as a Band 1 Top Firm in Securities and Class Actions, Legal 500’s Tier 1 Rankings for Securities and M&A Litigation, The National Law Journal’s Plaintiff’s Hot List and Trailblazers in Plaintiffs' Law, BTI Consulting Group’s Honor Roll of Most Feared Law Firms, The Legal Intelligencer’s Class Action Firm of the Year, Lawdragon’s Leading Plaintiff Financial Lawyers, and Law360’s Titans of the Plaintiffs Bar. The firm operates globally with offices in Pennsylvania and California. KTMC has recovered over $25 billion for our clients and the classes they represent.

CONTACT:
Jonathan Naji, Esq.
280 King of Prussia Road
Radnor, PA 19087
(484) 270-1453
[email protected]

May be considered attorney advertising in certain jurisdictions. Past results do not guarantee future outcomes.

BENSALEM, Pa., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Law Offices of Howard G. Smith continues its investigation on behalf of Alnylam Pharmaceuticals, Inc. (“Alnylam” or the “Company”) (NASDAQ: ALNY) investors concerning the Company's possible violations of federal securities laws.